GLP-1 Medication Comparison: Semaglutide, Tirzepatide and Liraglutide
GLP-1 medicines are not interchangeable. Ingredients, approved indications, dose schedules, evidence, contraindications, insurance rules and patient preferences differ.
What patients should know
Semaglutide is a GLP-1 receptor agonist available in weight-management Wegovy formulations. Tirzepatide activates both GIP and GLP-1 receptors and is marketed for weight management as Zepbound. Liraglutide is a daily GLP-1 injection marketed for weight management as Saxenda.
Clinical-trial averages do not predict an individual result. Real-world outcomes depend on tolerated dose, duration, adherence, nutrition, activity, sleep, underlying conditions and whether treatment can be continued.
Who may be evaluated
- Patients who meet product-specific criteria
- People comfortable with injection or tablet administration requirements
- Patients without personal/family MTC history or MEN 2 where contraindicated
- People able to follow titration and report significant adverse effects
Potential advantages
- Weekly and daily options
- Different mechanisms and expected efficacy ranges
- Some formulation-specific cardiovascular or sleep-apnea indications
- Structured side-effect and nutrition support
At-a-glance comparison
| Medication | Ingredient | Schedule | Weight-management role |
|---|---|---|---|
| Wegovy injection | Semaglutide | Weekly | Chronic weight management; additional formulation-specific indications |
| Wegovy tablets | Semaglutide | Daily | Adult weight reduction and maintenance under current labeling |
| Wegovy HD | Semaglutide 7.2 mg | Weekly | Higher-dose adult option under current labeling |
| Zepbound | Tirzepatide | Weekly | Chronic weight management and eligible obesity-related OSA |
| Saxenda | Liraglutide | Daily | Chronic weight management in labeled populations |
Safety and medical supervision
- Common adverse effects include nausea, vomiting, diarrhea, constipation and abdominal symptoms.
- Labels include important warnings involving pancreatitis, gallbladder disease, kidney injury related to dehydration and other risks.
- Semaglutide, tirzepatide and liraglutide products should not be combined with overlapping incretin therapies.
- Pregnancy requires discontinuation according to product labeling and clinician guidance.
This summary cannot replace the current FDA-approved prescribing information or an individualized medical evaluation. Tell the clinician about every prescription, over-the-counter medicine, supplement, allergy, pregnancy plan and relevant medical condition.
How W8MD can help
Personalized evaluation
W8MD reviews weight history, prior attempts, conditions, medicines, contraindications, sleep, nutrition, goals, insurance and cost.
Follow-up and maintenance
Care may include response monitoring, adverse-effect management, dose planning, nutrition, lean-mass goals, sleep-apnea evaluation and long-term maintenance.
Brooklyn / NYC: 2632 East 21st Street, Suite L3, Brooklyn, NY 11235 · 718-946-5500
Northeast Philadelphia: 1718 Welsh Road, 2nd Floor, Suite C, Philadelphia, PA 19115 · 215-676-2334
Medical evaluation is required. Eligibility, prescription, availability, coverage, price, response and adverse effects vary.
Related W8MD resources
Prescription hub · Medication guide · Semaglutide · Tirzepatide · Phentermine · Insurance · Medical weight loss · W8MD.com medication guides · NYC medical weight loss · Philadelphia medical weight loss · Anti-obesity medication encyclopedia
Frequently asked questions
Is tirzepatide a GLP-1?
Tirzepatide is a dual GIP/GLP-1 receptor agonist rather than a GLP-1-only medicine.
Is Ozempic the same as Wegovy?
They contain semaglutide but are different products with different FDA-approved indications and dosing information.
Which option costs less?
Cost varies by formulation, dose, pharmacy, insurance and available programs; the least expensive option is not automatically the safest or most sustainable.
Authoritative references
References are provided for education. Product labeling changes; clinicians and patients should consult the current FDA-approved label.
Request a W8MD callback
For appointments and time-sensitive questions, call Brooklyn at 718-946-5500 or Philadelphia at 215-676-2334. Do not submit urgent, confidential medical, insurance, financial or identifying information through this general form.
You must be logged in to post a comment.